Insight

Photo taken from Fred Saad/X

Sep 26, 2024, 12:37

Exclusive Interview With Fred Saad

MediaMedic shared on LinkedIn:

“Exclusive Insights on mHSPC Treatment: Interview with Fred Saad.

In a recent Media Medic interview, our colleague El Bachir Mourabit had the privilege to speak with Dr. Fred Saad about breakthrough advancements in metastatic hormone-sensitive prostate cancer (mHSPC) treatment.

Dr. Saad emphasized the importance of combining androgen deprivation therapy (ADT) with ARPIs like apalutamide, enzalutamide, or abiraterone for improved survival.

He also shared promising results from the Phase 3 ARINOTE study, showcasing darolutamide with ADT as a safe and effective option, especially for patients who may not tolerate chemotherapy.”

Source: MediaMedic/LinkedIn

abiraterone androgen deprivation therapy apalutamide cancer chemotherapy darolutamide El Bachir Mourabit Enzalutamide Fred Saad MediaMedic mHSPC treatment OncoDaily Oncology

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage